156 related articles for article (PubMed ID: 25077420)
1. A randomized, phase 1/2 trial of the safety, tolerability, and immunogenicity of bivalent rLP2086 meningococcal B vaccine in healthy infants.
Martinon-Torres F; Gimenez-Sanchez F; Bernaola-Iturbe E; Diez-Domingo J; Jiang Q; Perez JL
Vaccine; 2014 Sep; 32(40):5206-11. PubMed ID: 25077420
[TBL] [Abstract][Full Text] [Related]
2. A randomized, controlled, phase 1/2 trial of a Neisseria meningitidis serogroup B bivalent rLP2086 vaccine in healthy children and adolescents.
Nissen MD; Marshall HS; Richmond PC; Jiang Q; Harris SL; Jones TR; Jansen KU; Perez JL
Pediatr Infect Dis J; 2013 Apr; 32(4):364-71. PubMed ID: 23114369
[TBL] [Abstract][Full Text] [Related]
3. A phase 3, randomized, active-controlled study to assess the safety and tolerability of meningococcal serogroup B vaccine bivalent rLP2086 in healthy adolescents and young adults.
Ostergaard L; Lucksinger GH; Absalon J; Beeslaar J; Eiden J; Jansen KU; York LJ; Quinn A; Graversen ME; Perez JL
Vaccine; 2016 Mar; 34(12):1465-71. PubMed ID: 26845739
[TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity of a meningococcal B bivalent rLP2086 vaccine in healthy toddlers aged 18-36 months: a phase 1 randomized-controlled clinical trial.
Marshall HS; Richmond PC; Nissen MD; Jiang Q; Anderson AS; Jansen KU; Reynolds G; Ziegler JB; Harris SL; Jones TR; Perez JL
Pediatr Infect Dis J; 2012 Oct; 31(10):1061-8. PubMed ID: 22718089
[TBL] [Abstract][Full Text] [Related]
5. Meningococcal Serogroup B Bivalent rLP2086 Vaccine Elicits Broad and Robust Serum Bactericidal Responses in Healthy Adolescents.
Vesikari T; Østergaard L; Diez-Domingo J; Wysocki J; Flodmark CE; Beeslaar J; Eiden J; Jiang Q; Jansen KU; Jones TR; Harris SL; O'Neill RE; York LJ; Crowther G; Perez JL
J Pediatric Infect Dis Soc; 2016 Jun; 5(2):152-60. PubMed ID: 26407272
[TBL] [Abstract][Full Text] [Related]
6. A phase 2 open-label safety and immunogenicity study of a meningococcal B bivalent rLP2086 vaccine in healthy adults.
Marshall HS; Richmond PC; Nissen MD; Wouters A; Baber J; Jiang Q; Anderson AS; Jones TR; Harris SL; Jansen KU; Perez JL
Vaccine; 2013 Mar; 31(12):1569-75. PubMed ID: 23352429
[TBL] [Abstract][Full Text] [Related]
7. A phase 1, randomized, open-label, active-controlled trial to assess the safety of a meningococcal serogroup B bivalent rLP2086 vaccine in healthy adults.
Sheldon EA; Schwartz H; Jiang Q; Giardina PC; Perez JL
Hum Vaccin Immunother; 2012 Jul; 8(7):888-95. PubMed ID: 22832260
[TBL] [Abstract][Full Text] [Related]
8. Meningococcal serogroup B-specific responses after vaccination with bivalent rLP2086: 4 year follow-up of a randomised, single-blind, placebo-controlled, phase 2 trial.
Marshall HS; Richmond PC; Beeslaar J; Jiang Q; Jansen KU; Garcés-Sánchez M; Martinón-Torres F; Szenborn L; Wysocki J; Eiden J; Harris SL; Jones TR; Lee SS; Perez JL;
Lancet Infect Dis; 2017 Jan; 17(1):58-67. PubMed ID: 27745812
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity, Tolerability and Safety in Adolescents of Bivalent rLP2086, a Meningococcal Serogroup B Vaccine, Coadministered with Quadrivalent Human Papilloma Virus Vaccine.
Senders S; Bhuyan P; Jiang Q; Absalon J; Eiden JJ; Jones TR; York LJ; Jansen KU; O'Neill RE; Harris SL; Ginis J; Perez JL
Pediatr Infect Dis J; 2016 May; 35(5):548-54. PubMed ID: 26835974
[TBL] [Abstract][Full Text] [Related]
10. Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial.
Richmond PC; Marshall HS; Nissen MD; Jiang Q; Jansen KU; Garcés-Sánchez M; Martinón-Torres F; Beeslaar J; Szenborn L; Wysocki J; Eiden J; Harris SL; Jones TR; Perez JL;
Lancet Infect Dis; 2012 Aug; 12(8):597-607. PubMed ID: 22569484
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity, safety, and tolerability of the meningococcal serogroup B bivalent rLP2086 vaccine in adult laboratory workers.
Reiner DM; Bhuyan P; Eiden JJ; Ginis J; Harris S; Jansen KU; Jiang Q; Jones TR; O'Neill RE; York LJ; Perez JL
Vaccine; 2016 Feb; 34(6):809-13. PubMed ID: 26707218
[TBL] [Abstract][Full Text] [Related]
12. A Phase 2, Randomized, Active-controlled, Observer-blinded Study to Assess the Immunogenicity, Tolerability and Safety of Bivalent rLP2086, a Meningococcal Serogroup B Vaccine, Coadministered With Tetanus, Diphtheria and Acellular Pertussis Vaccine and Serogroup A, C, Y and W-135 Meningococcal Conjugate Vaccine in Healthy US Adolescents.
Muse D; Christensen S; Bhuyan P; Absalon J; Eiden JJ; Jones TR; York LJ; Jansen KU; O'Neill RE; Harris SL; Perez JL
Pediatr Infect Dis J; 2016 Jun; 35(6):673-82. PubMed ID: 26974889
[TBL] [Abstract][Full Text] [Related]
13. A bivalent Neisseria meningitidis recombinant lipidated factor H binding protein vaccine in young adults: results of a randomised, controlled, dose-escalation phase 1 trial.
Richmond PC; Nissen MD; Marshall HS; Lambert SB; Roberton D; Gruber WC; Jones TR; Arora A
Vaccine; 2012 Sep; 30(43):6163-74. PubMed ID: 22871351
[TBL] [Abstract][Full Text] [Related]
14. Neisseria meningitidis Serogroup B Vaccine, Bivalent rLP2086, Induces Broad Serum Bactericidal Activity Against Diverse Invasive Disease Strains Including Outbreak Strains.
Harris SL; Donald RG; Hawkins JC; Tan C; O'Neill R; McNeil LK; Perez JL; Anderson AS; Jansen KU; Jones TR
Pediatr Infect Dis J; 2017 Feb; 36(2):216-223. PubMed ID: 27846061
[TBL] [Abstract][Full Text] [Related]
15. Bivalent rLP2086 Vaccine (Trumenba(®)): A Review in Active Immunization Against Invasive Meningococcal Group B Disease in Individuals Aged 10-25 Years.
Shirley M; Dhillon S
BioDrugs; 2015 Oct; 29(5):353-61. PubMed ID: 26394633
[TBL] [Abstract][Full Text] [Related]
16. Neisseria meningitidis serogroup B bivalent factor H binding protein vaccine.
Brendish NJ; Read RC
Expert Rev Vaccines; 2015 Apr; 14(4):493-503. PubMed ID: 25703792
[TBL] [Abstract][Full Text] [Related]
17. Bactericidal activity of sera from adolescents vaccinated with bivalent rLP2086 against meningococcal serogroup B outbreak strains from France.
Taha MK; Hawkins JC; Liberator P; Deghmane AE; Andrew L; Hao L; Jones TR; McNeil LK; O'Neill RE; Perez JL; Jansen KU; Anderson AS
Vaccine; 2017 Mar; 35(11):1530-1537. PubMed ID: 28196734
[TBL] [Abstract][Full Text] [Related]
18. Safety of a quadrivalent meningococcal serogroups A, C, W and Y conjugate vaccine (MenACWY-CRM) administered with routine infant vaccinations: results of an open-label, randomized, phase 3b controlled study in healthy infants.
Abdelnour A; Silas PE; Lamas MR; Aragón CF; Chiu NC; Chiu CH; Acuña TH; Castrejón Tde L; Izu A; Odrljin T; Smolenov I; Hohenboken M; Dull PM
Vaccine; 2014 Feb; 32(8):965-72. PubMed ID: 24397906
[TBL] [Abstract][Full Text] [Related]
19. Multicomponent meningococcal serogroup B vaccine (4CMenB; Bexsero(®)): a review of its use in primary and booster vaccination.
Carter NJ
BioDrugs; 2013 Jun; 27(3):263-74. PubMed ID: 23575646
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study.
Santolaya ME; O'Ryan ML; Valenzuela MT; Prado V; Vergara R; Muñoz A; Toneatto D; Graña G; Wang H; Clemens R; Dull PM;
Lancet; 2012 Feb; 379(9816):617-24. PubMed ID: 22260988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
